You are here

TESARO Announces Second-Quarter 2018 Operating Results

  • ZEJULA® Q2 net sales totaled $54 million compared to $26 million for Q2 2017
  • QUADRA sNDA submission planned for Q4 2018
  • PRIMA Phase 3 ZEJULA monotherapy trial in first-line ovarian cancer regardless of biomarker status enrollment completed
  • Divestiture completed for VARUBI in U.S. and Canada for $40 million plus potential milestone payments and royalties
  • Data expected from TSR-042 (anti-PD-1) GARNET NSCLC and MSI-high endometrial expansion cohorts in 2H 2018; regulatory submission planned for 2019

WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today reported operating results for second-quarter 2018 and provided an update on the Company's commercial products and development programs.

“In the second quarter, we continued to execute on the ZEJULA launch in the U.S. and Europe, and we are changing the treatment paradigm for women with recurrent ovarian cancer,” said Lonnie Moulder, CEO of TESARO. “Following the results from our Phase 3 PRIMA trial, which is now fully enrolled, we hope to offer ZEJULA to women with newly diagnosed ovarian cancer, regardless of BRCA mutation status. Beyond ovarian cancer, our Phase 2 JASPER trial of ZEJULA in combination with an anti-PD-1 antibody in first-line, non-small cell lung cancer is ongoing and we expect to share data at a medical meeting in the first half of 2019. Our immuno-oncology pipeline is advancing quickly, led by TSR-042, our anti-PD-1 antibody, for which we are on track to submit a biologic license application (BLA) in 2019. Initial data from AMBER, a trial of our anti-TIM-3 antibody TSR-022 in combination with TSR-042, have been submitted for inclusion in the SITC Annual Meeting in November, and include results from lung cancer patients who have progressed on prior anti-PD-1 treatment.”

Recent Business Highlights

  • ZEJULA is the most utilized PARP inhibitor among ovarian cancer patients in the U.S., with more than 6,000 patients treated since its launch in April 2017. ZEJULA is now approved in 32 countries and reimbursed and launched in Germany, the U.K. and several other European countries.
  • The National Institute for Health and Care Excellence (NICE) made ZEJULA available to women with recurrent platinum-sensitive ovarian cancer in England and Wales via the Cancer Drugs Fund (CDF) in June.
  • At the ASCO meeting in June, results of the QUADRA study of ZEJULA monotherapy for the treatment of ovarian cancer were presented and included durable responses beyond patients with BRCA mutations and overall survival in the late-line ovarian cancer treatment setting. Results of the TOPACIO trial evaluating ZEJULA in combination with an anti-PD-1 antibody were also presented and highlighted promising activity in platinum-resistant/refractory ovarian cancer and triple-negative breast cancer beyond patients with BRCA mutations.
  • Enrollment was completed in the Phase 3 PRIMA trial of ZEJULA monotherapy for patients with first-line ovarian cancer regardless of biomarker status, and data from this study are anticipated in late 2019. Blinded, pooled interim safety data from PRIMA associated with a 200 milligram starting dose based upon baseline weight and platelet count were accepted for poster discussion at the European Society of Medical Oncology (ESMO) Annual Meeting in October.
  • TESARO divested the oral and intravenous formulations of VARUBI® (rolapitant) in the U.S. and Canada to TerSera Therapeutics LLC for $40 million plus potential milestone payments and royalties.
  • Data from the GARNET registration trial for TSR-042 (anti-PD-1 antibody) in patients with MSI-high endometrial cancer were accepted for poster discussion at the ESMO Annual Meeting in October.
  • Enrollment continues in the Phase 1 AMBER trial of TSR-022 (anti-TIM-3 antibody) in combination with TSR-042 in tumor-specific cohorts, including lung cancer patients who have progressed on prior PD-1 therapy.
  • In the Phase 1 CITRINO trial, dosing of TSR-033 (anti-LAG-3 antibody) in combination with TSR-042 was initiated.
  • At the end of June, TESARO drew the $200 million second tranche under its term loan agreement with Pharmakon Advisors, LP.

Second Quarter 2018 Financial Results

TESARO reported net product revenue of $56.5 million for the second quarter of 2018, compared to a total of $28.8 million for the second quarter of 2017, primarily due to growth in ZEJULA net revenue, which increased 108% to $53.9 million for the second quarter of 2018, compared to $25.9 million for the second quarter of 2017.

Research and development expenses increased to $97.6 million for the second quarter of 2018, compared to $71.4 million for the second quarter of 2017, primarily due to higher costs associated with the development of ZEJULA, TSR-042 and TSR-022, increased headcount, and research collaborations.

Selling, general and administrative expenses increased to $100.0 million for the second quarter of 2018, compared to $93.0 million for the second quarter of 2017, primarily due to increased headcount to support sales of ZEJULA in the U.S. and launches in Europe.

Operating expenses as described above include total non-cash, stock-based compensation expense of $28.4 million for the second quarter of 2018, compared to $23.5 million for the second quarter of 2017.

Net loss totaled $166.7 million, or ($3.04) per share, for the second quarter of 2018, compared to a net loss of $152.1 million, or ($2.82) per share, for the second quarter of 2017.

(in thousands, except per share amounts)Three Months Ended
June 30,
  2017  2018 
Product revenue, net  
ZEJULA® $  25,945 $  53,894 
VARUBI®/VARUBY®$  2,884 $  2,634 
Total product revenue, net$  28,829 $  56,528 
License, collaboration, and other revenue$  635 $  680 
Total revenues$  29,464 $  57,208 
Net loss$  (152,059)$  (166,651)
Net loss per share, basic and diluted$  (2.82)$  (3.04)

(in thousands)Three Months Ended
June 30,
  2017 2018
Cost of sales - product$   3,620$   13,513
Cost of sales - intangible asset amortization$   2,979$  1,498
Research and development (R&D)$  71,400$   97,608
Selling, general and administrative (SG&A)$  92,979$   100,033
Acquired in-process R&D$   7,000$  -

Cash and Cash Equivalents

As of June 30, 2018, TESARO had approximately $575.1 million in cash and cash equivalents, excluding $35 million received from TerSera in the third quarter upon closing of the VARUBI divestiture, and approximately 54.9 million outstanding shares of common stock.

2018 Financial Guidance

TESARO is revising its 2018 financial guidance to reflect the divestiture of VARUBI in the U.S. and Canada, updated timing of clinical milestone payments, and updated expectations for the market penetration of PARP inhibitors for ovarian cancer maintenance treatment in the U.S.

Total Revenue, net, worldwide (FY) $250 to $265 million
(previously $310 to $345 million)
ZEJULA (FY) $225 to $235 million
(previously $255 to $275 million)
ZEJULA (Q3) $58 to $62 million
Other revenue, including licensing and VARUBY oral (FY) $25 to $30 million
(previously $55 to $70 million)
Interest expense (FY) $50 to $60 million, including non-cash interest expense of $14 million

In the second quarter, TESARO’s cash and cash equivalents balance declined by approximately $120 million, excluding the impact of the $196 million (net of lender fees) received from the term loan facility. Quarterly declines in cash and cash equivalents are expected to moderate over the remainder of 2018 and TESARO anticipates year-end 2018 cash and cash equivalents to be approximately $400 million, including the $35 million upfront payment received in the third quarter from the divestiture of VARUBI.

Key Development Milestones

Gynecologic Cancer:

  • Submit QUADRA sNDA for treatment of late-line ovarian cancer beyond BRCAmut patients in Q4 2018
  • Initiate registrational trial of ZEJULA in combination with TSR-042 in platinum-resistant/refractory ovarian cancer in Q4 2018
  • Initiate enrollment in FIRST, a Phase 3 clinical trial of ZEJULA in combination with TSR-042 ± bevacizumab in first-line ovarian cancer, in September 2018
  • AVANOVA Phase 2 data of ZEJULA in combination with bevacizumab for treatment of recurrent ovarian cancer to be submitted for presentation at a medical meeting in 1H 2019
  • Report Phase 2 OVARIO data of ZEJULA in combination with bevacizumab in first-line ovarian cancer maintenance in late 2019
  • Report Phase 3 PRIMA data of ZEJULA in first-line ovarian cancer maintenance in late 2019
  • Report additional data from MSI-high endometrial cohort of the GARNET trial of TSR-042 at the ESMO Annual Meeting in October and submit a BLA to FDA in 2H 2019

Lung Cancer:

  • Initiate Phase 2 registration enabling trial of TSR-042 versus standard of care in first-line NSCLC in early 2019
  • Report additional data from lung cancer cohort of the GARNET trial of TSR-042 in NSCLC at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November
  • Report initial data from the AMBER trial of TSR-022 in combination with TSR-042 at the SITC Annual Meeting
  • Following availability of initial data in Q4 2018 from Phase 2 JASPER study of ZEJULA in combination with an anti-PD-1 inhibitor, submit data for presentation at a medical meeting in 1H 2019

Breast Cancer:

  • Submit BRAVO data for publication in Q4 2018
  • Complete protocol development for registration study of ZEJULA in combination with TSR-042 in breast cancer

Prostate Cancer:

  • Janssen is advancing trials of ZEJULA in prostate cancer to support U.S. and EU regulatory filings in 2019

Immuno-oncology Pipeline:

  • Continue to enroll CITRINO trial (combination of TSR-033 plus TSR-042) and report Phase 1 monotherapy dose-escalation data for TSR-033 at the SITC Annual Meeting
  • Advance IND-enabling studies of PD-1/LAG-3 bi-specific antibody (TSR-075)

Today's Conference Call and Webcast
TESARO will host a conference call to discuss second quarter operating results and provide an update on its commercial products and development programs today at 4:15 P.M. Eastern time. The accompanying slide presentation and live webcast of the conference call can be accessed by visiting the TESARO website at The call can be accessed by dialing (877) 853-5334 (U.S. and Canada) or (970) 315-0307 (international). A replay of the webcast will be archived on the Company's website for 30 days following the call.

About ZEJULA (Niraparib)
ZEJULA (niraparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.  In preclinical studies, ZEJULA concentrates in the tumor relative to plasma, delivering greater than 90% durable inhibition of PARP 1/2 and a persistent antitumor effect. Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), including some fatal cases, was reported in patients treated with ZEJULA. Discontinue ZEJULA if MDS/AML is confirmed.  Hematologic adverse reactions (thrombocytopenia, anemia and neutropenia), as well as cardiovascular effects (hypertension and hypertensive crisis) have been reported in patients treated with ZEJULA. Monitor complete blood counts to detect hematologic adverse reactions, as well as to detect cardiovascular disorders, during treatment.  ZEJULA can cause fetal harm and females of reproductive potential should use effective contraception. Please see full prescribing information, including additional important safety information, available at

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit, and follow us on Twitter and LinkedIn.

TESARO Contacts:
Jennifer Davis
Vice President, Corporate Communications & Investor Relations
+1.781.325.1116 or

Kate Rausch
Director, Investor Relations
+1.781.257.2505 or

Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding: our 2018 revenue, interest expense, and cash balance guidance; the expected decline in our cash and cash equivalents balance; the design and expected timing of initiation, enrollment, and data readouts and publications from our various ongoing and planned ZEJULA, TSR-042, TSR-033, TSR-022, combination, and other clinical trials; the expected timing of our various BLA, sNDA and other regulatory filings; and our expectation to achieve our various development milestones. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our research and development programs, future financial and other results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks related to the acceptance of our products in the marketplace, competition, the uncertainties inherent in the execution and completion of clinical trials, uncertainties surrounding the timing of availability of data from clinical trials, uncertainties surrounding potential actions by regulatory authorities, uncertainties regarding the expected timing and magnitude of certain expenditures, risks related to manufacturing and supply, risks related to intellectual property, the terms of our term loan facility, other matters that could affect our financial results, the results of our ongoing and planned development programs, and/or the availability or commercial potential of our products and drug candidates. TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO's Annual Report on Form 10-K for the year ended December 31, 2017 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.

Unaudited Condensed Consolidated Statements of Operations 
(in thousands, except per share amounts) 
    Three Months Ended
June 30,
 Six Months Ended
June 30,
     2017   2018   2017   2018   
 Product revenue, net:          
  ZEJULA®  $  25,945  $  53,894  $  25,945  $  102,763   
  VARUBI®/VARUBY®     2,884     2,634     5,023     3,937   
 Total product revenue, net    28,829     56,528     30,968     106,700   
 License, collaboration and other revenues    635     680     1,569     250   
Total revenues    29,464     57,208     32,537     106,950   
 Cost of sales - product    3,620     13,513     4,064     23,510   
 Cost of sales - intangible asset amortization    2,979     1,498     3,469     2,935   
 Research and development (1)    71,400     97,608     137,522     194,363   
 Selling, general and administrative (1)    92,979     100,033     162,241     193,640   
 Acquired in-process research and development    7,000     -     7,000     -   
Total expenses    177,978     212,652     314,296     414,448   
Loss from operations    (148,514)    (155,444)    (281,759)    (307,498)  
Interest and other income (expense), net    (3,467)    (11,215)    (6,893)    (21,561)  
Loss before income taxes    (151,981)    (166,659)    (288,652)    (329,059)  
Provision (benefit) for income taxes    78     (8)    132     408   
Net loss $  (152,059) $  (166,651) $  (288,784) $  (329,467)  
Net loss per share applicable to          
 common stockholders - basic and diluted $  (2.82) $  (3.04) $  (5.36) $  (6.02)  
Weighted-average number of common          
 shares used in net loss per share applicable
to common stockholders - basic and diluted
    53,982     54,845     53,834     54,731   
(1) Expenses include the following amounts of non-cash stock-based compensation expense:      
 Research and development $  7,862  $  8,195  $  14,987  $  16,009   
 Selling, general and administrative    15,646     20,214     26,922     38,528   


Unaudited Condensed Consolidated Balance Sheets
(in thousands)
   December 31, June 30,
    2017  2018 
Current assets:    
 Cash and cash equivalents $  643,095 $  575,104 
 Accounts receivable    53,416    35,679 
 Inventories    57,939    87,406 
 Other current assets    33,511    36,924 
 Assets held for sale    -    22,299 
Total current assets    787,961    757,412 
Intangible assets, net    56,384    36,624 
Property and equipment, net    9,652    10,657 
Restricted cash    2,552    2,556 
Other assets    5,636    3,204 
 Total assets $  862,185 $  810,453 
Liabilities and stockholders' equity    
Current liabilities:    
 Accounts payable $  4,172 $  12,925 
 Accrued expenses    154,808    159,447 
 Deferred revenue, current    324    437 
 Other current liabilities    6,902    11,371 
Total current liabilities    166,206    184,180 
Convertible notes, net    143,446    149,793 
Long-term debt, net    293,659    490,125 
Deferred revenue, non-current    211    164 
Other non-current liabilities    9,577    7,739 
 Total liabilities    613,099    832,001 
Total stockholders' equity (deficit)    249,086    (21,548)
 Total liabilities and stockholders' equity (deficit) $  862,185 $  810,453 
Thursday, August 2, 2018 - 16:05